NCT00290706 - A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 7, 2006

Primary Completion Date

February 11, 2011

Study Completion Date

September 5, 2012

Conditions

Lymphoma

Interventions

DRUG

bortezomib

Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.

DRUG

gemcitabine hydrochloride

Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.

Trial Locations (3)

Northwestern University, Chicago

Veterans Affairs Medical Center - Lakeside Chicago, Chicago

University of Chicago Cancer Research Center, Chicago